Pharos iBio Co., Ltd. (KOSDAQ:388870)
South Korea · Delayed Price · Currency is KRW 6,300.00
-330.00 (-4.98%)
At close: May 29, 2026
Pharos iBio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
81.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 300.00M | 243.00M | 426.32% |
| Dec 31, 2021 | 57.00M | -130.68M | -69.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daehan Nupharm | 205.39B |
| Sinsin Pharmaceutical | 118.65B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 108.89B |
| Hwail Pharmaceutical | 107.87B |
| KOREA PHARMA | 91.42B |
| Sam-A Pharm. | 70.93B |
| Polaris AI Pharma | 63.94B |
| Samik Pharmaceutical Company LTD. | 61.48B |